# Rimidi Diabetes

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/rimidi-diabetes

- Industry: Software
- Headquarters: Atlanta, US
- Website: www.rimidi.com
- Total disclosed funding: $7.9M
- Latest round: Series A (Jul 10, 2018)
- Investors on record: 5

## About

Rimidi Diabetes Inc. focuses on chronic disease management and remote patient monitoring via an integrated software platform that enhances healthcare delivery, particularly for those managing type 2 diabetes.Founded in 2012 and headquartered in Atlanta, US, Rimidi Diabetes Inc. specializes in chronic disease management solutions. The company was co-founded by Lucienne Ide, who has a background in healthcare technology. In July 2018, Rimidi raised USD 6.58 mn in Series A funding from investors including Eli Lilly & Company and Turner Investments, which marked a significant step in their growth.Rimidi specializes in chronic disease management and remote patient monitoring through an integrated software platform designed to work seamlessly with existing electronic health records (EHR). Their offerings include configurable Remote Patient Monitoring (RPM) programs featuring enhanced decision support and patient prioritization. The platform empowers healthcare providers to improve engagement and health outcomes in chronic disease populations, particularly those managing type 2 diabetes.Rimidi generates revenue through a subscription-based model targeting healthcare providers and institutions utilizing their platform for chronic disease management. Clients subscribe for access to the software and tools, enabling long-term business-to-business (B2B) partnerships focused on enhancing patient care and outcomes. Specific pricing plans are undisclosed, but the emphasis remains on delivering impactful solutions for providers.Following the recent funding round in July 2018, Rimidi plans to enhance its product offerings and expand its reach into new markets. The raised capital will support the development of new features for their platform and potentially facilitate entry into additional geographic regions. The focus remains on improving chronic disease management, with particular emphasis on better outcomes for patients managing type 2 diabetes.

## Funding rounds

- Series A, Jul 10, 2018, $6.6M — Eli Lilly & Company, Village Capital, The JumpFund, Cox Ventures SA, Turner Investments LLC
- Seed, Oct 24, 2014, $1.3M — Village Capital

## Investors

- Village Capital (https://capitalatlas.ai/funds/village-capital) — Seed, Series A
- Eli Lilly & Company — Series A
- The JumpFund (https://capitalatlas.ai/funds/the-jumpfund) — Series A
- Cox Ventures SA — Series A
- Turner Investments LLC — Series A